Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Revelation Biosciences, Inc.

We develop immunologic therapeutics and diagnostics designed to make the world a healthier place 


	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-3.64K -	-1.63M 44,718.58%	-11.99M 635.16%	-10.83M 9.65%	-120.25K 98.89%
depreciation and amortization			16.78K -	25.05K 49.26%	25.05K 0.00%
deferred income tax					-749.66K -
stock based compensation		43.85 -	470.88K 1,073,787.06%	301.12K 36.05%	155.72K 48.29%
change in working capital	3.64K -	-80.50K 2,312.67%	356.22K 542.53%	-730.97K 305.20%	982.13K 234.36%
accounts receivables
inventory
accounts payables		30.13K -	-269.64K 994.80%	-666.04K 147.01%	749.66K 212.55%
other working capital	3.64K -	-110.63K 3,140.98%	625.86K 665.72%	-64.93K 110.37%	232.47K 458.04%
other non cash items		1.50M -	52.38K 96.50%	14.96K 71.44%	-7.58M 50,763.62%
net cash provided by operating activities		-215.07K -	-11.09M 5,056.63%	-11.22M 1.16%	-7.29M 35.06%
investments in property plant and equipment			-131.96K -
acquisitions net
purchases of investments		-74.04M -
sales maturities of investments			525.29K -
other investing activites			-525.29K -
net cash used for investing activites		-74.04M -	-131.96K 99.82%
debt repayment		-15K -		-3.30M -
common stock issued	-10K -	74.25M 742,597.23%	600.00K 99.19%	11.71M 1,852.22%	14.03M 19.78%
common stock repurchased				-7.65M -	-5K 99.93%
dividends paid				-7.65M -
other financing activites	10K -	8.87K 11.31%	7.40M 83,388.94%	22.09M 198.26%
net cash used provided by financing activities		74.26M -	8.00M 89.22%	15.20M 89.86%	14.03M 7.72%
effect of forex changes on cash		-74.24M -
net change in cash		-74.23M -	-3.22M 95.67%	3.98M 223.64%	6.74M 69.39%
cash at beginning of period		74.24M -	4.49M 93.95%	1.27M 71.62%	5.25M 312.09%
cash at end of period		11.73K -	1.27M 10,763.55%	5.25M 312.09%	11.99M 128.28%
operating cash flow		-215.07K -	-11.09M 5,056.63%	-11.22M 1.16%	-7.29M 35.06%
capital expenditure			-131.96K -
free cash flow		-215.07K -	-11.22M 5,117.99%	-11.22M 0.03%	-7.29M 35.06%

COM:REVBIOSCIENCES

Revelation Biosciences, Inc.

Last Close

0.75

22/11 21:00

Market Cap

2.91M

Beta: -

Volume Today

115.97K

Avg: -

Preview